Zogenix Spikes After Its GW-Rivaling Anti-Seizure Drug Outperforms

Zogenix (ZGNX) stock rocketed almost 25% in premarket trading Thursday after its anti-seizure drug outperformed expectations — leading shares of rival GW Pharmaceuticals (GWPH) to dip.

X

In premarket trading on the stock market today, Zogenix stock popped 24.6%, near 57.70. GW, which recently grabbed approval for its anti-seizure drug, tumbled 3.4%, near 140.

Both biotech companies are working on treatments for Dravet syndrome. GW’s drug — derived from the cannabis plant — grabbed approval last month. But Zogenix is hot on its heels.

Early Thursday, Zogenix said a regimen using its drug, called ZX008, reduced convulsive monthly seizures by an average 62.7% vs. a 1.2% reduction among patients on a placebo.

IBD Newsletters
Get exclusive IBD analysis and action news daily.

SIGN UP NOW!

IBD Newsletters
Get exclusive IBD analysis and action news daily.

Market Prep

Tech Report

Please enter a valid email address

Please select a newsletter

GO

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

x

Thank You!

You will now receive IBD Newsletters

ALL DONE!

Something Went Wrong!

Please contact customer service

CLOSE

InvestorsNewslettersSignUp.boot( {“api_url”:”https://services.investors.com/services/JSONPService.asmx/UpdateEmailPreference”} );

The study also met its secondary goals with 53.5% of patients reporting their monthly convulsive seizures dropped by at least half. Nearly a third of patients, 32.6%, experienced a 75% reduction in their monthly convulsive seizures.

At the median, the longest seizure-free interval was 22 days vs. 13 days on the placebo.

More to follow.

RELATED:

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Best Stocks To Buy And Watch? Start Here

The post Zogenix Spikes After Its GW-Rivaling Anti-Seizure Drug Outperforms appeared first on Investor's Business Daily.

Comments are closed.